GENFIT Joins CAC Mid 60 and SBF 120 Indices

GENFIT, a biopharmaceutical company focused on rare liver diseases, has been added to the CAC Mid 60 and SBF 120 indices on Euronext Paris. The inclusion follows a review by the Scientific Council of the Indices and will take effect on September 18, 2026. This development marks a significant moment for GENFIT as it increases its market capitalization and visibility among institutional investors.

Pascale Prigent, CEO of GENFIT, expressed satisfaction with the inclusion, citing growing investor confidence in the company's strategy. The CAC Mid 60 and SBF 120 indices are highly regarded, representing key mid-sized companies and major securities, respectively. GENFIT’s entry into these indices signifies its growing impact in the French equity market.